Literature DB >> 18725604

Stopping anticoagulant therapy after an unprovoked venous thromboembolism.

Clive Kearon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18725604      PMCID： PMC2518190          DOI： 10.1503/cmaj.081080

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.

Authors:  Simon McRae; Huyen Tran; Sam Schulman; Jeff Ginsberg; Clive Kearon
Journal:  Lancet       Date:  2006-07-29       Impact factor: 79.321

2.  D-dimer testing to determine the duration of anticoagulation therapy.

Authors:  Gualtiero Palareti; Benilde Cosmi; Cristina Legnani; Alberto Tosetto; Carlotta Brusi; Alfonso Iorio; Vittorio Pengo; Angelo Ghirarduzzi; Corrado Pattacini; Sophie Testa; Anthonie W A Lensing; Armando Tripodi
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

Review 3.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

4.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

Authors:  C Kearon; M Gent; J Hirsh; J Weitz; M J Kovacs; D R Anderson; A G Turpie; D Green; J S Ginsberg; P Wells; B MacKinnon; J A Julian
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

5.  Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences.

Authors:  Mirjam Locadia; Patrick M M Bossuyt; Peep F M Stalmeier; Mirjam A G Sprangers; Carlo J J van Dongen; Saskia Middeldorp; Ivan Bank; Jan van der Meer; Karly Hamulyák; Martin H Prins
Journal:  Thromb Haemost       Date:  2004-12       Impact factor: 5.249

6.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

7.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.

Authors:  Trevor Baglin; Roger Luddington; Karen Brown; Caroline Baglin
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

8.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 9.  Natural history of venous thromboembolism.

Authors:  Clive Kearon
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

10.  Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.

Authors:  Marc A Rodger; Susan R Kahn; Philip S Wells; David A Anderson; Isabelle Chagnon; Grégoire Le Gal; Susan Solymoss; Mark Crowther; Arnaud Perrier; Richard White; Linda Vickars; Tim Ramsay; Marisol T Betancourt; Michael J Kovacs
Journal:  CMAJ       Date:  2008-08-26       Impact factor: 8.262
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.